New Delhi, India, Mar 17: In a significant step toward advancing AI-driven biomedical healthcare innovation and international research collaboration, the Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has secured a prestigious Indo-Swedish research grant under the Department of Biotechnology–Vinnova collaborative program. The project is titled ‘AI-based bio-design for developing peptide therapeutics against pneumonia-causing pathogens with experimental validation’.
Researchers plan to validate the computational predictions through in vitro experiments and lung organoid assays for real-world applications. It will enable the researchers to evaluate peptide efficacy and safety. In addition, the research will contribute to a deep scientific understanding of pathogen-host interactions and peptide-based drug design.
Commenting on this prestigious collaboration opportunity to revolutionise the healthcare industry by leveraging advanced technology, Dr. Docent N. Arul Murugan said, “In the coming years, biomedical discovery will be heavily transformed by artificial intelligence’s contribution. This India-Swedish collaboration displays IIIT-Delhi’s commitment to utilising computational biology, AI, and Gen-AI to address critical health challenges on a global scale. The integration of advanced machine learning and experimental validation can accelerate the discovery of peptide therapeutics to combat pneumonia-causing pathogens.”
